←
Fahima Dossa, MD PhD461 posts
Fahima Dossa, MD PhD avatar

Fahima Dossa, MD PhD

@fdossa

Surgical Oncologist & Clinical Epidemiologist @CedarsSinai @DeptSurgeryCS | Soft Tissue Sarcoma & GI Malignancies | 🇨🇦

◷ Joined October 2010▧ 58 Photos and videos
Erman Akkus avatar
⟳ Fahima Dossa, MD PhD retweeted
Erman Akkus@Erman_Akkus·Jul 11

Systemic therapy, gastrectomy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy versus systemic therapy alone for gastric cancer with limited peritoneal metastases (PERISCOPE II): final results of a multicentre RCT phase III thelancet.com/journals/lanon…

Hannah Abrams, MD avatar
⟳ Fahima Dossa, MD PhD retweeted
Hannah Abrams, MD@HannahRAbrams·Jun 1

I was skeptical of virtual twin studies but @fdossa convinced me they have a role, especially for our patients with rare cancer. Look forward to seeing what’s next out of this line of research #ASCO26 #sarcoma 👇🏻

Post attachment
Jun Gong, MD avatar
⟳ Fahima Dossa, MD PhD retweeted
Jun Gong, MD@jgong15·May 31

A much needed breakthrough for our pts with #PDAC 👏👏. Glad to see amongst investigators for this important study, our fearless #GImedonc leader @DrHendifar as an author in the @NEJM manuscript @OncoAlert @DrArsenOsipov @AGangiMD @_BrainyMD_ @CFerroneMD @fdossa @CedarsSinaiMed

NEJM@NEJMMay 31

Presented at #ASCO26: Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: nej.md/4nWaxvM @ASCO

Post attachment
Dr. Nina Niu Sanford avatar
⟳ Fahima Dossa, MD PhD retweeted
Dr. Nina Niu Sanford@NiuSanford·May 9

This is a great read on watch & wait in rectal cancer. B/c patients with local regrowth after WW have higher rates of distant mets, there has been an intuitive fear that regrowth is causal (i.e delaying TME permits metastatic seeding hence WW risky). The authors here argue (and I agree) that regrowth/metastases are manifestations of intrinsic aggressive tumor biology because: 1) no difference in time to surgery in patients w pCR/regrowth who developed mets vs. those who didn't (if delay were causal, would expect longer delay in patients who developed M1). 2) in OPRA secondary analysis, patients with cCR underwent least surgery/longest observation while those with incomplete response had surgery most frequently/immediately. But outcomes still tracked with response phenotype not timing of surgery (i.e. cCR did best). 3) tumor response itself is prognostic (i.e. even when all pts undergo TME, more regression after neoadjuvant therapy --> better DFS/DM). 4) modern tumor evolution data suggest metastatic spread mostly happens early. 5) chemo/radioresistance appears to be linked to metastatic potential (i.e. regrowth is a marker of aggressive biology not the mechanism itself). IMO a persuasive argument against hypothesis that regrowth seeds metastasis, but rather biology=dominant driver. @OncoAlert

Watch and Wait for Rectal Cancer: A Risky Gamble or a Safe Strategy for Patients With a Near-Complete Response? | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JCO…

Fahima Dossa, MD PhD avatar
Fahima Dossa, MD PhD@fdossa·May 7

Thrilled to finally see this out - 🚨#Sarculator bayesian update for more refined risk estimates in extremity soft tissue sarcoma App📱update and @LancetOncology pub: sciencedirect.com/science/ar… Phenomenal work @DCalleMD, Gabriele Tine, et al. ! 👏🏽👏🏽

The #Sarculator app update is now live! This comes together with our @TheLancetOncol paper introducing #BayeSarc, a Bayesian sequential learning approach to refine prognostication in extremity soft tissue #sarcoma. Paper: sciencedirect.com/science/ar…
App: apps.apple.com/it/app/sarcul…

Post attachmentPost attachment
Fahima Dossa, MD PhD avatar
Fahima Dossa, MD PhD@fdossa·Mar 10

Building on terrific #SSO2026 and @TARPSWG meetings, check out our📄on current dx & tx strategies for soft tissue sarcoma @BjsOpen, including recent technical advances and multiD approaches @ctosociety @SocSurgOnc @ESSOnews @_CSSO @FioreDoc @alegronchi academic.oup.com/bjsopen/art…